BESPONSA®

(Inotuzumab ozogamicin)

Documentation

Patented
Approved 2017
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: ADC
Target: CD22
Indication Category: Cancer

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA